ReviewJournal of clinical pathology2007
The significance of substance P in physiological and malignant haematopoiesis.
Review in Journal of clinical pathology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 57 citations in OpenAlex.
- Neuro-immune interactions in gastrointestinal oncology: Mechanisms, challenges, and therapeutic potential.Innovation (Cambridge (Mass.)) · 2026Review
- Neuro-immune interactions in colorectal cancer: mechanistic insights and therapeutic implications within the tumor immune microenvironment.Frontiers in immunology · 2026Review
- Progress in Research on Alleviating the Symptoms Associated With Advanced Cancer Using Traditional Chinese Medicine.Pain research & management · 2026Review
- The neuro-immune axis in cancer: from mechanisms to therapeutic opportunities.Journal of hematology & oncology · 2025Review
- Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications.Signal transduction and targeted therapy · 2025Review
- Role of Neurotransmitters in Steady State Hematopoiesis, Aging, and Leukemia.Stem cell reviews and reports · 2025Review
- Nervous system-gut microbiota-immune system axis: future directions for preventing tumor.Frontiers in immunology · 2025Review
- The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.International journal of molecular sciences · 2023Review
- Neuro-immune interactions and immuno-oncology.Trends in cancer · 2023Review
- Trigeminal nerve-derived substance P regulates limbal stem cells by the PI3K-AKT pathway.iScience · 2023Article
- Substance P/neurokinin-1 receptor pathway blockade ameliorates limbal stem cell deficiency by modulating mTOR pathway and preventing cell senescence.Stem cell reports · 2022Article
- Detection of neurokinin-1 receptor by immunohistochemistry in canine mammary gland tumours.Veterinary medicine and science · 2020Article
- The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia.Journal of clinical medicine · 2020Review
- Functional, Diagnostic and Therapeutic Aspects of Gastrointestinal Hormones.Gastroenterology research · 2019Review
- Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in breast cancer.Molecular biology reports · 2019Article
- Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists.Investigational new drugs · 2019Article
- Neural Regulation of Bone and Bone Marrow.Cold Spring Harbor perspectives in medicine · 2018Review
- Review
- Role for substance p-based nociceptive signaling in progenitor cell activation and angiogenesis during ischemia in mice and in human subjects.Circulation · 2012Article
- The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer.TheScientificWorldJournal · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of substance P (SP) in physiological haematopoiesis is well established. However, it also seems to be important in the neoplastic transformation of bone marrow, leading to the development of acute leukaemia in children, and also metastases to bone marrow of solid tumours (particularly neuroblastoma and breast cancer) in early stages of these diseases. This review summarises the available data on SP involvement in both processes. In the future, SP antagonists may be used as anti-neoplastic drugs, for example by direct or indirect blocking of tumour cell proliferation through inhibition of growth factor production and interleukin-1b synthesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.